Drugs /

fate-nk100

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for fate-nk100

Fate-nk100 has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating fate-nk100, 2 are phase 1 (1 open).

EGFR Expression, ERBB2 Amplification, and HER2 Overexpression are the most frequent biomarker inclusion criteria for fate-nk100 clinical trials.

Acute myeloid leukemia and malignant solid tumor are the most common diseases being investigated in fate-nk100 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Fate-Nk100
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Fate-Nk100
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating fate-nk100 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
allogeneic cd3- cd19- cd57+ nkg2c+ nk cells fate-nk100

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.